Prognostic value of lymph node ratio in patients with advanced epithelial ovarian cancer

Gynecologic Oncology

Volumn 135, Issue 3, 2014, Pages 435-440

  Ataseven, Beyhan ^a   Grimm, Christoph ^a   Harter, Philipp ^a   Prader, Sonia ^a   Traut, Alexander ^a   Heitz, Florian ^a   Du Bois, Andreas ^a  

^a KLINIKEN ESSEN MITTE   (Germany)

Author keywords

Lymph node ratio; Ovarian cancer; Prognosis; Systematic lymphadenectomy

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CALCULATION; CANCER PROGNOSIS; CANCER REGISTRY; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPH NODE RATIO; MAJOR CLINICAL STUDY; OPERATIVE BLOOD LOSS; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; CANCER STAGING; LYMPH NODE; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS;

FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84920755009     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.10.003     Document Type: Article

References (22)

1. Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 2013;105:175-201.
2. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 2009;115:1234-44.
3. Harter P, Muallem ZM, Buhrmann C, Lorenz D, Kaub C, Hils R, et al. Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer. Gynecol Oncol 2011;121:615-9.
4. du Bois A, Reuss A, Harter P, Pujade-Lauraine E, Ray-Coquard I, Pfisterer J. Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. J Clin Oncol 2010; 28:1733-9.
5. Trimbos B, Timmers P, Pecorelli S, Coens C, Ven K, van der Burg M, et al. Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial. J Natl Cancer Inst 2010;102:982-7.
6. Thigpen T, duBois A, McAlpine J, DiSaia P, Fujiwara K, Hoskins W, et al. First-line therapy in ovarian cancer trials. Int J Gynecol Cancer 2011;21:756-62.
7. Deng J, Sun D, Pan Y, Zhang L, Zhang R, Wang D, et al. Ratio between negative and positive lymph nodes is suitable for evaluation the prognosis of gastric cancer patients with positive node metastasis. PLoS ONE 2012;7:e43925.
8. Dings PJ, Elferink MA, Strobbe LJ, de Wilt JH. The prognostic value of lymph node ratio in node-positive breast cancer: a Dutch nationwide population-based study. Ann Surg Oncol 2013;20:2607-14.
9. Hou X, Wei JC, Xu Y, Luo RZ, Fu JH, Zhang LJ, et al. The positive lymph node ratio predicts long-term survival in patients with operable thoracic esophageal squamous cell carcinoma in China. Ann Surg Oncol 2013;20:1653-9.
10. Xing Y, Badgwell BD, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, et al. Lymph node ratio predicts disease-specific survival in melanoma patients. Cancer 2009; 115:2505-13.
11. Taylor MD, Lapar DJ, Thomas CJ, Persinger M, Stelow EB, Kozower BD, et al. Lymph node ratio predicts recurrence and survival after R0 resection for non-small cell lung cancer. Ann Thorac Surg 2013;96:1163-70.
12. Mahdi H, Thrall M, Kumar S, Hanna R, Seward S, Lockhart D, et al. The prognostic impact of the ratio of positive lymph nodes on survival of epithelial ovarian cancer patients. J Surg Oncol 2011;103:724-9.
13. Therneau TM, Grambsch PM, Fleming TR. Martingale-based residuals for survival models. Biometrika 1990;77:147-60.
14. Aletti GD, Santillan A, Eisenhauer EL, Hu J, Aletti G, Podratz KC, et al. A new frontier for quality of care in gynecologic oncology surgery:multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. Gynecol Oncol 2007;107:99-106.
15. Panici PB, Maggioni A, Hacker N, Landoni F, Ackermann S, Campagnutta E, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 2005;97:560-6.
16. Prat J. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 2014;124:1-5.
17. Pereira A, Irishina N, Perez-Medina T, Magrina JF, Magtibay PM, Kovaleva A, et al. Defining the optimal lymphadenectomy cut-off value in epithelial ovarian cancer staging surgery utilizing a mathematical model of validation. Eur J Surg Oncol 2013;39:290-6.
18. Madbouly KM, Abbas KS, Hussein AM. Metastatic lymph node ratio in stage III rectal carcinoma is a valuable prognostic factor even with less than 12 lymph nodes retrieved: a prospective study. American journal of surgery 2014;207:824-31.
19. Choi BG, Kim CY, Cho SH, Kim HJ, Koh YS, Kim JC, et al. Impact of lymph node ratio as a valuable prognostic factor in gallbladder carcinoma, focusing on stage IIIB gallbladder carcinoma. J Korean Surg Soc 2013;84:168-77.
20. Jeon MJ, Yoon JH, Han JM, Yim JH, Hong SJ, Song DE, et al. The prognostic value of the metastatic lymph node ratio andmaximal metastatic tumor size in pathological N1a papillary thyroid carcinoma. Eur J Endocrinol 2013;168:219-25.
21. Ryu IS, Song CI, Choi SH, Roh JL, Nam SY, Kim SY. Lymph node ratio of the central compartment is a significant predictor for locoregional recurrence after prophylactic central neck dissection in patients with thyroid papillary carcinoma. Ann Surg Oncol 2014;21:277-83.
22. du Bois A, Rochon J, Pfisterer J, Hoskins WJ. Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review. Gynecol Oncol 2009;112:422-36.